Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NRXP stock hub

NRx Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

NRXPis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
101.7M
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
NRXP
In the news

Latest news · NRXP

Recent company headlines from major financial publishers.

Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E4.1
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROEn/a
P25 -105.6P50 -46.5P75 -3.1
ROICn/a
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All NRXP market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
188
Groups with data
11
Currency
USD
Showing 188 of 188 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

22
MetricValue
Cik
0001719406
Company name
NRx Pharmaceuticals, Inc.
Country
United States
Country code
US
Cusip
629444209
Employees
29
Enterprise value
$94.6M
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
Isin
US6294442099
Last refreshed
2026-05-10
Market cap
$101.7M
Market cap category
Micro-Cap
Price
$3.08
Price currency
USD
Rev Per Employee
42,241.38x
Sector
Healthcare
Sic
2834
Symbol
NRXP
Website
https://www.nrxpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

5
MetricValue
Earnings Yield
-28.13%
EV/Sales
77.21x
FCF yield
-13.87%
Forward P/E
4.09x
P/S ratio
83.06x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

10
MetricValue
Gross margin
58.78%
Gross Profit
$720,000
Net Income
$-28.6M
Net Income Growth Quarters
1%
Net Income Growth Years
0%
Pretax Margin
-2,336.49%
Profit Per Employee
$-986,966
ROA
-121.8
Roa5y
-175.2
ROCE
103.6

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

6
MetricValue
Cagr1y
56.39%
Cagr3y
-20.43%
Cagr5y
-60.8%
EPS Growth Quarters
1
EPS Growth Years
4
Revenue Growth Years
0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

16
MetricValue
Asset Turnover
$0.15
Assets
$13M
Cash
$7.8M
Current Assets
$8.9M
Current Liabilities
$28.6M
Debt
$631,000
Equity
$-15.9M
Interest Coverage
-24.13
Liabilities
$28.9M
Long Term Assets
$4.1M
Long Term Liabilities
$315,000
Net Cash
$7.2M
Net Cash By Market Cap
$7.04
Tangible Book Value
$-18.7M
Tangible Book Value Per Share
$-0.59
WACC
15.77

Liquidity

Current-asset coverage and working-capital efficiency metrics.

5
MetricValue
Current ratio
0.31
Net Working Capital
$-27.2M
Quick ratio
0.28
Working Capital
$-19.7M
Working Capital Turnover
$-0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-101.06%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

39
MetricValue
1Y total return
56.35%
200-day SMA
2.5
3Y total return
-49.63%
50-day SMA
2.35
50-day SMA vs 200-day SMA
50under200
5Y total return
-99.07%
All Time High
769.9
All Time High Change
-99.6%
All Time High Date
2020-12-22
All Time Low
1.1
All Time Low Change
180%
All Time Low Date
2024-10-16
ATR
0.19
Beta
2.02
Beta1y
2.09
Beta2y
0.82
Ch YTD
13.65
High
3.13
High52
3.84
High52 Date
2025-10-07
High52ch
-19.79%
Low
3.01
Low52
1.62
Low52 Date
2026-03-09
Low52ch
90.12%
Ma50ch
30.95%
Premarket Change Percent
0
Premarket Price
$3.06
Price vs 200-day SMA
23.1%
RSI
65.65
RSI Monthly
42.61
RSI Weekly
65.04
Sharpe ratio
0.9x
Sortino ratio
1.58
Total Return
-101.06%
Tr YTD
13.65
Tr1m
38.12%
Tr1w
-0.32%
Tr3m
61.26%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

12
MetricValue
Analyst Count
4
Analyst Count Top
1
Analyst Price Target Top
$45
Analyst Ratings
Strong Buy
Analyst Ratings Top
Strong Buy
Earnings EPS Estimate
$-0.09
Earnings Revenue Estimate
23,303,336x
Operating Income
$-16.2M
Operating margin
-1,321.5
Price target
$38.25
Price Target Change
$1,142
Price Target Change Top
$1,361

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

11
MetricValue
Float
24,244,733%
Float Percent
73.39%
Net Borrowing
4,679,000
Shares Insiders
5.4%
Shares Institutions
7.1%
Shares Out
33,034,735
Shares Qo Q
30.27%
Shares Yo Y
101.06%
Short Float
13.4%
Short Ratio
3.57
Short Shares
9.83

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

60
MetricValue
Adjusted FCF
$-14.9M
Average Volume
1,220,467.95x
Bv Per Share
-0.5
Ch1m
38.12
Ch1w
-0.32
Ch1y
56.35
Ch3m
61.26
Ch3y
-49.63
Ch5y
-99.07
Ch6m
25.71
Change
0.65%
Change From Open
0
Close
3.06
Days Gap
0.65
Depreciation Amortization
70,000
Dollar Volume
3,031,967.4
Earnings Date
2026-05-14
Earnings Time
amc
EBIT
$-16.2M
EBITDA
$-16.1M
EPS
$-1.34
F Score
2
FCF
$-14.1M
FCF EV Yield
-14.92x
FCF Per Share
$-0.43
Financing CF
23,276,000
Fiscal Year End
December
Founded
2,015
Goodwill
1,793,000
Investing CF
-2,810,000
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-03-23
Last Report Date
2025-12-31
Last Split Date
2024-04-02
Last Split Type
Reverse
Last10k Filing Date
2026-03-23
Ma150
2.41
Ma150ch
27.91%
Ma20
2.87
Ma20ch
7.21%
Net CF
6,354,000
Next Earnings Date
2026-05-22
Open
3.08
Optionable
Yes
Position In Range
60.87
Post Close
3.08
Postmarket Change Percent
-0.32
Postmarket Price
$3.07
Ppne
696,000
Pre Close
3.06
Price Date
2026-05-08
Relative Volume
0.81x
Revenue
1,225,000x
SBC By Revenue
67.67x
Share Based Comp
829,000
Tr6m
25.71%
Us State
Delaware
Volume
984,405
Z Score
-37.88
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does NRXP pay a dividend?

Capital-return profile for this ticker.

Performance

NRXP stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+56.3%
S&P 500 1Y: n/a
3Y total return
-49.6%
S&P 500 3Y: n/a
5Y total return
-99.1%
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns NRXP?

Insider, institutional, and short-interest positioning.

Institutional ownership
+7.1%
Float: +73.4% of shares outstanding
Insider ownership
+5.4%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+13.4%
3.6 days to cover
Y/Y dilution
+101.1%
Negative means the company is buying back shares.
Technical

NRXP momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
65.6
Neutral momentum band
Price vs 200-day MA
+23.1%
50/200-day relationship not available
Beta (5Y)
2.02
More volatile than the market
Sharpe ratio
0.90
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About NRXP

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NRXP stock rating?

NRx Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NRXP analysis?

The full report lives at /stocks/NRXP/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NRXP?

The latest report frames NRXP around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NRXP page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.